BDNF, neuroplasticity, and anxiolytic mechanisms in nootropic peptide research

Semax and Selank are synthetic peptides developed from ACTH and tuftsin respectively, with substantial preclinical and limited clinical evidence for nootropic and anxiolytic effects. Both peptides are administered primarily via intranasal spray due to direct transport along the olfactory nerve to central nervous system structures. Research focuses on upregulation of BDNF (brain-derived neurotrophic factor) and NGF (nerve growth factor), modulation of the GABAergic system, and regulation of monoamine neurotransmitters.

Mechanism

Semax (MEHFPGP) is an ACTH(4-7) analogue that upregulates BDNF and NGF expression in the hippocampus and cortex, enhances dopaminergic and serotonergic tone, and reduces oxidative stress markers. Selank (TKPRPGP) is a tuftsin analogue that modulates GABAergic transmission (particularly GABA-A receptor subunit expression), suppresses IL-6 and TNF-α, and reduces anxiety indices in multiple validated behavioural paradigms.

Plain-language summary

Semax and Selank are Soviet-era synthetic peptides developed in Russia during the 1970s–80s and still prescribed there today for stroke recovery, anxiety disorders, and cognitive decline. Unlike stimulants (which flood the brain with dopamine) or sedatives (which suppress neuronal activity), these peptides work by upregulating the brain's own growth and repair factors. Semax stimulates the production of BDNF — brain-derived neurotrophic factor — a protein critical for learning, memory, and neuronal survival. Selank modulates the GABA system, the brain's primary calming pathway, producing anxiolytic effects without the sedation or dependence risk of benzodiazepines. A key practical advantage: both are administered as nasal sprays, bypassing the need for injections.

Research protocols

Protocol	Peptides	Duration	Dosage	Endpoint
Morris Water Maze (Spatial Memory)	Semax	14 days	50–200 µg per animal (mouse); 0.1 mg/kg (rat) · Once daily, intranasal	Escape latency (seconds), platform quadrant dwell time during probe trial, BDNF mRNA (qPCR) in hippocampal tissue at sacrifice
Elevated Plus Maze (Anxiety)	Selank	7 days	100–300 µg per animal · Once daily, intranasal or SC	Open-arm time (%), open-arm entries (%), serum corticosterone (ELISA), hippocampal BDNF protein (Western blot)
14-Day BDNF Upregulation Study	Semax, Selank	14 days	100 µg per animal per dose · Twice daily	Hippocampal and prefrontal BDNF protein (ELISA), TrkB phosphorylation (Western blot), open-field locomotion (to control for sedation)

Key studies

2010

Selank affects the expression of genes that modulate the balance between anxiety and depression

Selank significantly upregulated genes involved in GABA-A receptor subunit expression and BDNF in rat prefrontal cortex after 5-day intranasal treatment, correlating with anxiolytic behaviour in EPM and light-dark box tests.

PMID 20857282

2006

Semax, an ACTH4-10 analogue, affects the expression of BDNF and its receptor TrkB

Intranasal Semax produced a 2.5–3× increase in BDNF mRNA and protein in the hippocampus and frontal cortex of healthy rats at 24 and 72 hours post-administration.

PMID 16466354

Verdict

✓Pros

Nasal spray delivery — no injections required, lower barrier than most peptide categories
Selank shows anxiolytic potency comparable to benzodiazepines in animal models, without sedation or withdrawal
Semax demonstrates 2–3× increase in hippocampal BDNF in published rodent studies
Both compounds have been used clinically in Russia with decades of post-marketing observation
Fast onset for anxiolytic effects: animal models show reduced anxiety within 30–60 minutes of intranasal dosing
Cognitive and mood effects often reported together — broad neurological profile from two compounds

×Cons

Most human trial data comes from Russian-language studies, many not available in peer-reviewed Western journals
Short half-life requires consistent twice-daily dosing — missed doses disrupt the protocol
Nasal absorption varies significantly between individuals based on mucosal health and dosing technique
No Western regulatory approval (FDA, EMA)
Limited EU vendor availability compared to healing peptides — stock issues are common
Subjective effects can be subtle; self-researchers report highly variable responses

Legal status

Semax and Selank are unscheduled in most EU countries and are not controlled substances. They are not approved by the EMA or FDA as medicines. In Russia, they are approved prescription drugs available in pharmacies. EU self-researchers can legally purchase them as research compounds in most jurisdictions — verify your local laws.

FAQ

Why is intranasal the preferred route for Semax and Selank?

Intranasal delivery exploits the olfactory nerve pathway for direct CNS transport, achieving CSF concentrations significantly higher than equivalent IV doses. Both peptides are rapidly degraded peripherally, making direct CNS delivery critical for central effects.

How do Semax and Selank differ mechanistically?

Semax primarily drives BDNF/NGF expression and enhances monoaminergic (dopamine, serotonin) signalling — making it more relevant to cognitive enhancement and neuroprotection research. Selank acts predominantly on the GABAergic system and cytokine regulation, making it more relevant to anxiety and neuroimmune research.